In a filing, Calidi Biotherapeutics Inc revealed its CEO and Chairman of the Board Camaisa Allan unloaded Company’s shares for reported $16200.0 on Dec 17 ’24. In the deal valued at $1.62 per share,10,000 shares were sold. As a result of this transaction, Camaisa Allan now holds 66,712 shares worth roughly $ 86058.48.
H.C. Wainwright initiated its Calidi Biotherapeutics Inc [CLDI] rating to a Buy in a research note published on November 22, 2023; the price target was $11. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early October with a ‘”an Outperform”‘ rating.
Price Performance Review of CLDI
On Tuesday, Calidi Biotherapeutics Inc [AMEX:CLDI] saw its stock fall -5.15% to $1.29. Over the last five days, the stock has lost -2.27%. Calidi Biotherapeutics Inc shares have risen nearly 12.17% since the year began. Nevertheless, the stocks have fallen -75.88% over the past one year. While a 52-week high of $16.80 was reached on 02/12/25, a 52-week low of $0.58 was recorded on 01/30/25. SMA at 50 days reached $1.2836, while 200 days put it at $1.5765.
Levels Of Support And Resistance For CLDI Stock
The 24-hour chart illustrates a support level at 1.2333, which if violated will result in even more drops to 1.1767. On the upside, there is a resistance level at 1.3833. A further resistance level may holdings at 1.4767. The Relative Strength Index (RSI) on the 14-day chart is 53.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1492, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.04%. Stochastics %K at 78.82% indicates the stock is a holding.
